Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Post-marketing Surveillance to Assess Safety & Efficacy of Perampanel in Indian Patients as An Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Patients With Epilepsy Aged 12 Years or Older

NCT03836924 is registered in ClinicalTrials.gov with Eisai Pharmaceuticals India Pvt. Ltd as lead sponsor.

NCT NCT03836924
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03836924 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Post-marketing Surveillance to Assess Safety & Efficacy of Perampanel in Indian Patients as An Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Patients With Epilepsy Aged 12 Years or Older
Lead sponsor
Eisai Pharmaceuticals India Pvt. Ltd
Phase
Observational
Overall status
Completed
Start date
February 18, 2019
Completion date
March 1, 2020
Enrollment
200 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy, partial onset seizures